Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 12/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | EGFR | P00533 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | CDK1 | P06493 | 1/20 | 0.52 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.50 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL36835 | 0.98 | ERN1 (0.61) | ERN1ALDH1A1MAPTKDM4EEGFR | |
| Hydroquinone SCHEMBL11562733 | 0.95 | ERN1 (0.59) | ERN1ALDH1A1MAPTKDM4EEGFR | |
| Formamide SCHEMBL28912568 | 0.91 | ERN1 (0.55) | ERN1ALDH1A1MAPTKDM4EEGFR | |
| Formaldehyde SCHEMBL28912569 | 0.91 | ERN1 (0.55) | ERN1ALDH1A1MAPTKDM4EEGFR | |
| Sulfurous Acid SCHEMBL11594092 | 0.89 | ERN1 (0.53) | ERN1ALDH1A1MAPTKDM4EEGFR | |
| SCHEMBL29082634 | 0.84 | TRIM24 (0.50) | ERN1ALDH1A1MAPTKDM4EEGFR | |
| Glycine SCHEMBL28062857 | 0.82 | ERN1 (0.47) | ERN1ALDH1A1MAPTKDM4EEGFR | |
| SCHEMBL6640732 | 0.80 | ERN1 (0.70) | ERN1 | |
| SCHEMBL29952866 | 0.80 | TRIM24 (0.47) | ERN1ALDH1A1MAPTKDM4EEGFR | |
| SCHEMBL7913737 | 0.80 | TRIM24 (0.47) | ERN1ALDH1A1MAPTKDM4EEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2015647-A2 | IRON COMPLEX FOR USE IN THE TREATMENT AND/OR PREVENTION OF NUTRITIONAL DISORDERS | UNILEVER N.V. (NL) | 2009-01-21 | — | — | EP | disclosed |
| WO-2006037449-A2 | IRON COMPLEX FOR USE IN THE TREATMENT AND/OR PREVENTION OF NUTRITIONAL DISORDERS | UNILEVER N.V. (NL) | 2006-04-13 | — | — | WO | disclosed |
| US-20060078594-A1 | Iron complex | CONOPCO, INC., D/B/A UNILEVER | 2006-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060078594-A1 | Iron complex | SLC40A1, FECH, TFRC | ERN1 4428/4885ALDH1A1 3385/4885MAPT 3579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.